ARLINGTON, Va. — Surescripts, a national health intelligence network, has released its 2025 Annual Impact Report, highlighting gains in health data interoperability, prior authorization automation and prescription affordability across the U.S.
The company said it processed 30.5 billion health intelligence transactions in 2025, a 12.3 percent increase from the prior year. Those transactions connected 2.32 million healthcare professionals and provider organizations and reached nearly every insured American, according to the report.
“When we talk about advancing healthcare interoperability, we are talking about strengthening the connection between people—between providers, payers and the patients they serve,” said Frank Harvey, Chief Executive Officer, Surescripts. “This year’s report shows what’s possible when we bring healthcare together around a shared purpose: accelerating informed decisions that help keep care on track.”
One of the report’s headline developments is the growing use of automated prior authorization. The technology now returns approvals in as little as 18 seconds for certain medications, reducing the delays that traditionally slowed access to treatment. In 2025, the system supported 83 medications, with 45,275 prescribers enabled across 20 health systems.
“Innovation, like automated prior authorization, which returns approvals in just 18 seconds, means patients have one less barrier to navigate and enables faster access to the therapy they need. That’s the kind of impact that can meaningfully improve care,” Harvey said.
Use of Real-Time Prescription Benefit tools also continued to expand. In 2025, 973,463 prescribers received a combined one billion real-time benefit responses. The system also informed 11.9 million specialty prescriptions with coverage and cost data, helping patients save more than $55 million in total.
According to the report, patients saved an average of $77 per prescription when a lower-cost alternative was identified, and $817 per specialty prescription.
The report also highlighted trends in prescribing patterns for GLP-1 medications used to treat Type 2 diabetes and obesity. Prescriptions for the drugs surged nationwide, with the fastest growth recorded in Puerto Rico, Vermont, Massachusetts, Washington and Wisconsin.
Pharmacists also saw increased adoption of digital tools. In 2025, they completed 201,999 RxTransfer transactions, with nearly a quarter of retail pharmacy locations enabled for the service. Surescripts noted that in January 2026 alone, RxTransfer usage doubled compared to the total volume recorded during all of 2025, signaling accelerating momentum in pharmacy workflow automation.
Overall, the company said the findings reflect broader industry efforts to modernize healthcare administration, reduce manual processes and speed access to medications for patients nationwide.
